Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01718743 · OUTCOME

Number of Participants Incidence of New Primary Malignancy

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months

What was measured

Count of participants

Groups in this outcome

Treatment (Ixazomib Citrate, Lenalidomide)

Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ixazomib Citrate, Lenalidomide)64

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
Count of participants
groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    OG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months
title
Number of Participants Incidence of New Primary Malignancy
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice